BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 38671504)

  • 1. Deciphering the role of FUS::DDIT3 expression and tumor microenvironment in myxoid liposarcoma development.
    Ranji P; Jonasson E; Andersson L; Filges S; Luna Santamaría M; Vannas C; Dolatabadi S; Gustafsson A; Myklebost O; Håkansson J; Fagman H; Landberg G; Åman P; Ståhlberg A
    J Transl Med; 2024 Apr; 22(1):389. PubMed ID: 38671504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear expression of FLT1 and its ligand PGF in FUS-DDIT3 carrying myxoid liposarcomas suggests the existence of an intracrine signaling loop.
    Andersson MK; Göransson M; Olofsson A; Andersson C; Aman P
    BMC Cancer; 2010 Jun; 10():249. PubMed ID: 20515481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory mechanisms, expression levels and proliferation effects of the FUS-DDIT3 fusion oncogene in liposarcoma.
    Åman P; Dolatabadi S; Svec D; Jonasson E; Safavi S; Andersson D; Grundevik P; Thomsen C; Ståhlberg A
    J Pathol; 2016 Apr; 238(5):689-99. PubMed ID: 26865464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells.
    Engström K; Willén H; Kåbjörn-Gustafsson C; Andersson C; Olsson M; Göransson M; Järnum S; Olofsson A; Warnhammar E; Aman P
    Am J Pathol; 2006 May; 168(5):1642-53. PubMed ID: 16651630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of inhibitors regulating cell proliferation and FUS-DDIT3 expression in myxoid liposarcoma using combined DNA, mRNA, and protein analyses.
    Svec D; Dolatabadi S; Thomsen C; Cordes N; Shannon M; Fitzpatrick P; Landberg G; Åman P; Ståhlberg A
    Lab Invest; 2018 Jul; 98(7):957-967. PubMed ID: 29588491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ.
    Göransson M; Andersson MK; Forni C; Ståhlberg A; Andersson C; Olofsson A; Mantovani R; Aman P
    Oncogene; 2009 Jan; 28(2):270-8. PubMed ID: 18850010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FUS-DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma.
    Trautmann M; Menzel J; Bertling C; Cyra M; Isfort I; Steinestel K; Elges S; Grünewald I; Altvater B; Rossig C; Fröhling S; Hafner S; Simmet T; Åman P; Wardelmann E; Huss S; Hartmann W
    Clin Cancer Res; 2017 Oct; 23(20):6227-6238. PubMed ID: 28637688
    [No Abstract]   [Full Text] [Related]  

  • 8. Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression.
    Göransson M; Elias E; Ståhlberg A; Olofsson A; Andersson C; Aman P
    Int J Cancer; 2005 Jul; 115(4):556-60. PubMed ID: 15688424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The FUS-DDIT3 Interactome in Myxoid Liposarcoma.
    Yu JSE; Colborne S; Hughes CS; Morin GB; Nielsen TO
    Neoplasia; 2019 Aug; 21(8):740-751. PubMed ID: 31220736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Requirement for YAP1 signaling in myxoid liposarcoma.
    Trautmann M; Cheng YY; Jensen P; Azoitei N; Brunner I; Hüllein J; Slabicki M; Isfort I; Cyra M; Berthold R; Wardelmann E; Huss S; Altvater B; Rossig C; Hafner S; Simmet T; Ståhlberg A; Åman P; Zenz T; Lange U; Kindler T; Scholl C; Hartmann W; Fröhling S
    EMBO Mol Med; 2019 May; 11(5):. PubMed ID: 30898787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DDIT3/CHOP and the sarcoma fusion oncoprotein FUS-DDIT3/TLS-CHOP bind cyclin-dependent kinase 2.
    Bento C; Andersson MK; Aman P
    BMC Cell Biol; 2009 Dec; 10():89. PubMed ID: 20017906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FUS-DDIT3 Fusion Oncoprotein Expression Affects JAK-STAT Signaling in Myxoid Liposarcoma.
    Dolatabadi S; Jonasson E; Andersson L; Luna Santamaría M; Lindén M; Österlund T; Åman P; Ståhlberg A
    Front Oncol; 2022; 12():816894. PubMed ID: 35186752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paratesticular myxoid/round cell liposarcoma harboring type 3 DDIT3-FUS fusion gene: report of a very rare case.
    Zozumi M; Nakai M; Matsuda I; Hao H; Tsukamoto Y; Shiraishi Y; Nojima M; Yamamoto S; Hirota S
    Pathol Res Pract; 2013 Feb; 209(2):124-7. PubMed ID: 23276404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FUS-CHOP Promotes Invasion in Myxoid Liposarcoma through a SRC/FAK/RHO/ROCK-Dependent Pathway.
    Tornin J; Hermida-Prado F; Padda RS; Gonzalez MV; Alvarez-Fernandez C; Rey V; Martinez-Cruzado L; Estupiñan O; Menendez ST; Fernandez-Nevado L; Astudillo A; Rodrigo JP; Lucien F; Kim Y; Leong HS; Garcia-Pedrero JM; Rodriguez R
    Neoplasia; 2018 Jan; 20(1):44-56. PubMed ID: 29190494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cryptic EWSR1::DDIT3 fusion in myxoid liposarcoma: Potential pitfalls with FISH and cytogenetics.
    Ibstedt S; de Mattos CBR; Köster J; Mertens F
    Genes Chromosomes Cancer; 2023 Mar; 62(3):167-170. PubMed ID: 36379683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The FUS::DDIT3 fusion oncoprotein inhibits BAF complex targeting and activity in myxoid liposarcoma.
    Zullow HJ; Sankar A; Ingram DR; Samé Guerra DD; D'Avino AR; Collings CK; Lazcano R; Wang WL; Liang Y; Qi J; Lazar AJ; Kadoch C
    Mol Cell; 2022 May; 82(9):1737-1750.e8. PubMed ID: 35390276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myxoid liposarcoma-associated EWSR1-DDIT3 selectively represses osteoblastic and chondrocytic transcription in multipotent mesenchymal cells.
    Suzuki K; Matsui Y; Higashimoto M; Kawaguchi Y; Seki S; Motomura H; Hori T; Yahara Y; Kanamori M; Kimura T
    PLoS One; 2012; 7(5):e36682. PubMed ID: 22570737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation.
    de Graaff MA; Yu JS; Beird HC; Ingram DR; Nguyen T; Juehui Liu J; Bolshakov S; Szuhai K; Åman P; Torres KE; Lev D; Nielsen TO; Bovée JV; Lazar AJ; Somaiah N
    Lab Invest; 2016 Aug; 96(8):885-94. PubMed ID: 27270875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment and characterization of NCC-MLPS1-C1: a novel patient-derived cell line of myxoid liposarcoma.
    Noguchi R; Yoshimatsu Y; Sei A; Hirabayashi K; Ozawa I; Kikuta K; Kondo T
    Hum Cell; 2021 Mar; 34(2):667-674. PubMed ID: 33146842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myxoid liposarcoma with pleomorphic cells: Report of two cases with molecular confirmation of FUS gene rearrangements.
    Uchihashi K; Matsuyama A; Nakayama M; Sakamoto A; Shiba E; Hisaoka M
    Pathol Res Pract; 2016 Nov; 212(11):1067-1070. PubMed ID: 27515548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.